These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 26068969

  • 1. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
    Guerram M, Jiang ZZ, Yousef BA, Hamdi AM, Hassan HM, Yuan ZQ, Luo HW, Zhu X, Zhang LY.
    Oncotarget; 2015 Sep 08; 6(26):21865-77. PubMed ID: 26068969
    [Abstract] [Full Text] [Related]

  • 2. A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway.
    Tian HL, Yu T, Xu NN, Feng C, Zhou LY, Luo HW, Chang DC, Le XF, Luo KQ.
    Cancer Lett; 2010 Nov 01; 297(1):18-30. PubMed ID: 20494511
    [Abstract] [Full Text] [Related]

  • 3. Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
    Huang B, Yip WK, Wei N, Luo KQ.
    Cancer Lett; 2020 Oct 10; 490():1-11. PubMed ID: 32585412
    [Abstract] [Full Text] [Related]

  • 4. Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer.
    Lu Q, Zhang P, Zhang X, Chen J.
    Int J Mol Med; 2009 Dec 10; 24(6):773-80. PubMed ID: 19885617
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 6. A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells.
    Chu B, Liu F, Li L, Ding C, Chen K, Sun Q, Shen Z, Tan Y, Tan C, Jiang Y.
    Cell Death Dis; 2015 Mar 12; 6(3):e1686. PubMed ID: 25766325
    [Abstract] [Full Text] [Related]

  • 7. Potential anticancer activity of tanshinone IIA against human breast cancer.
    Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J, Wang W.
    Int J Cancer; 2005 Sep 20; 116(5):799-807. PubMed ID: 15849732
    [Abstract] [Full Text] [Related]

  • 8. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

  • 9. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.
    Yadav B, Taurin S, Larsen L, Rosengren RJ.
    Int J Oncol; 2012 Nov 19; 41(5):1723-32. PubMed ID: 22971638
    [Abstract] [Full Text] [Related]

  • 10. A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor.
    Yu T, Zhou Z, Mu Y, de Lima Lopes G, Luo KQ.
    Cancer Lett; 2014 Apr 28; 346(1):94-103. PubMed ID: 24374015
    [Abstract] [Full Text] [Related]

  • 11. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
    Zhou NN, Tang J, Chen WD, Feng GK, Xie BF, Liu ZC, Yang D, Zhu XF.
    Life Sci; 2012 May 22; 90(19-20):770-5. PubMed ID: 22525372
    [Abstract] [Full Text] [Related]

  • 12. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells.
    Greenshields AL, Fernando W, Hoskin DW.
    Exp Mol Pathol; 2019 Apr 22; 107():10-22. PubMed ID: 30660598
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J, Chen Y, Meng T, Ma L, Meng L, Wang X, Yu T, Zask A, Shen J, Yu K.
    Oncotarget; 2016 Oct 11; 7(41):67071-67086. PubMed ID: 27563814
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy.
    Wang Q, Luo M, Wei N, Chang A, Luo KQ.
    Mol Pharm; 2019 Sep 03; 16(9):3873-3886. PubMed ID: 31389706
    [Abstract] [Full Text] [Related]

  • 19. Tanshinone IIA induces growth inhibition and apoptosis in gastric cancer in vitro and in vivo.
    Chen J, Shi DY, Liu SL, Zhong L.
    Oncol Rep; 2012 Feb 03; 27(2):523-8. PubMed ID: 22038415
    [Abstract] [Full Text] [Related]

  • 20. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar 03; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.